China Development Bank Capital specializing in direct, mezzanine, and fund of fund investments.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Founded in August 2009 with the approval of the State Council, China Development Bank Capital Co.,Ltd.(CDB Capital) is a wholly owned subsidiary of China Development Bank (CDB). With a registered capital of RMB 60.6 billion, CDB Capital is principally engaged in investment and asset management. By the end of 2017, CDB Capital’s total assets added up to RMB 136.2 billion, with nearly RMB 280 billion in assets under management and a cumulative investment of RMB 268 billion in 580 projects. Since its establishment, CDB Capital has been committed to supporting national strategies, cooperating with CDB, steadily expanding its business scope, deepening internal reform, strengthening market-oriented operations and aligning strategy with profitability. With the goal of growing into a national investment platform and first class capital management institution, CDB Capital has played a unique role in serving national strategies and CDB&s;s reform and development.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
10/2022 | Govion Technology | Series C | - |
2/2023 | Guanan Information | Venture Round | 44.3M |
12/2022 | XCMG Hanyun | Series B | 43M |
1/2022 | X-EPIC | Venture Round | - |
3/2022 | Shenzhen Shifeng | Series A | 0 |
7/2021 | VirtAI Tech | Series B | 0 |
8/2022 | Sineva | Series C | 74.4M |
1/2023 | HighTide | Series C | 107M |
1/2023 | Percipio.xyz | Series C | - |
1/2023 | Digital Language Lab Service Provider | Venture Round | 57.8M |
8/2018 | Epwk | Series B | 0 |
12/2022 | Eswin | Series C | 574.9M |
1/2017 | Baixing Pingan Yaofang | Angel Round | 432.4k |
1/2023 | Aiste | Venture Round | 44.3M |
5/2017 | Wacai.com | Series C | 0 |
2/2017 | G7 | Private Equity Round | 45M |
12/2022 | SPIC | Series B | 645.9M |
6/2022 | Winicssec | Venture Round | - |
10/2018 | celula | Angel Round | 0 |
10/2022 | Wenge Group | Series E | 0 |
4/2023 | B&a;C Chemical | Series C | 87.1M |
7/2019 | Lepu Bio | Series A | 0 |
1/2021 | ChengRui | Series A | - |
1/2016 | Hive Box | Series A | 383.3M |
1/2023 | HighTide Therapeutics | Series C | 107M |
2/2018 | JD Logistics | Venture Round | 2.5B |
12/2021 | Eswin | Series C | 392.6M |
8/2021 | CasiVision Technology | Series C | 0 |
6/2022 | Winicssec | Venture Round | - |
3/2022 | Shenzhen Shifeng | Series A | 0 |
1/2022 | X-EPIC | Venture Round | - |
12/2021 | Eswin | Series C | 0 |
8/2021 | CasiVision Technology | Series C | 0 |
7/2021 | VirtAI Tech | Series B | 0 |
1/2021 | ChengRui | Series A | - |
7/2019 | Lepu Bio | Series A | 0 |
10/2018 | celula | Angel Round | 0 |
8/2018 | Epwk | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|